DaVita Inc
Change company Symbol lookup
Select an option...
DVA DaVita Inc
ACIU AC Immune SA
KPRX Kiora Pharmaceuticals Inc
ATIF ATIF Holdings Ltd
BHR Braemar Hotels & Resorts Inc
QTEKW QualTek Services Equity Warrant Exp 14th Feb 2027 *W EXP 02/14/2027
ALR Alerislife Inc
CCEP Coca-Cola Europacific Partners PLC
QQQ Invesco QQQ Trust
BARK Bark Inc
Go

Health Care : Health Care Providers & Services | Mid Cap Value
Company profile

DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company's operations are comprised of its U.S. dialysis and related lab services business (U.S. dialysis business), its U.S. ancillary services and strategic initiatives, its international operations (ancillary services), and corporate administrative support. The U.S. dialysis business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). The Company provides dialysis and administrative services and related laboratory services. Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services supporting integrated kidney care and kidney care initiatives outside of dialysis, clinical research programs, and transplant software business as well as international operations.

Closing Price
$89.58
Day's Change
-3.34 (-3.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
92.24
Day's Low
89.16
Volume
(Below Average)
Volume:
568,525

10-day average volume:
705,606
568,525

Company Profile

DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company's operations are comprised of its U.S. dialysis and related lab services business (U.S. dialysis business), its U.S. ancillary services and strategic initiatives, its international operations (ancillary services), and corporate administrative support. The U.S. dialysis business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). The Company provides dialysis and administrative services and related laboratory services. Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services supporting integrated kidney care and kidney care initiatives outside of dialysis, clinical research programs, and transplant software business as well as international operations.

Valuation Ratios

Price/Earnings (TTM)
11.31x
Price/Sales (TTM)
0.72x
Price/Book (MRQ)
13.90x
Price/Cash Flow (TTM)
4.76x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
4.7M
Previous Month
5.0M
Percent of Float
5.26%
Days to Cover
5.6103 Days

Share Information

DVA is in a share class of common stock
Float
88.5M
Shares Outstanding
91.3M
Institutions Holding Shares
726
91.96%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Pamela M. Arway
  • Javier J. RodriguezCEO
  • Joel AckermanCFO
  • John D. WinstelCAO
  • James O. HeartyCCO

Address

Insider Trading

During the most recent quarter, 20K shares were bought, and 3K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.